347 related articles for article (PubMed ID: 33181118)
1. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease.
Mendez-Sanchez N; Arrese M; Gadano A; Oliveira CP; Fassio E; Arab JP; Chávez-Tapia NC; Dirchwolf M; Torre A; Ridruejo E; Pinchemel-Cotrim H; Castellanos Fernández MI; Uribe M; Girala M; Diaz-Ferrer J; Restrepo JC; Padilla-Machaca M; Dagher L; Gatica M; Olaechea B; Pessôa MG; Silva M
Lancet Gastroenterol Hepatol; 2021 Jan; 6(1):65-72. PubMed ID: 33181118
[TBL] [Abstract][Full Text] [Related]
2. Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease.
Arab JP; Dirchwolf M; Álvares-da-Silva MR; Barrera F; Benítez C; Castellanos-Fernandez M; Castro-Narro G; Chavez-Tapia N; Chiodi D; Cotrim H; Cusi K; de Oliveira CPMS; Díaz J; Fassio E; Gerona S; Girala M; Hernandez N; Marciano S; Masson W; Méndez-Sánchez N; Leite N; Lozano A; Padilla M; Panduro A; Paraná R; Parise E; Perez M; Poniachik J; Restrepo JC; Ruf A; Silva M; Tagle M; Tapias M; Torres K; Vilar-Gomez E; Costa Gil JE; Gadano A; Arrese M
Ann Hepatol; 2020; 19(6):674-690. PubMed ID: 33031970
[TBL] [Abstract][Full Text] [Related]
3. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease.
Nan Y; An J; Bao J; Chen H; Chen Y; Ding H; Dou X; Duan Z; Fan J; Gao Y; Han T; Han Y; Hu P; Huang Y; Huang Y; Jia J; Jiang J; Jiang Y; Li J; Li J; Li R; Li S; Li W; Li Y; Lin S; Liu J; Liu S; Lu L; Lu Q; Luo X; Ma X; Rao H; Ren H; Ren W; Shang J; Shi L; Su M; Wang B; Wang R; Wei L; Wen Z; Wu B; Wu J; Xin S; Xing H; Xu J; Yan M; Yang J; Yang J; Yang L; Yang Y; Yu Y; Zhang L; Zhang L; Zhang X; Zhang Y; Zhang Y; Zhao J; Zhao S; Zheng H; Zhou Y; Zhou Y; Zhuang H; Zuo W; Xu X; Qiao L
J Hepatol; 2021 Aug; 75(2):454-461. PubMed ID: 34019941
[TBL] [Abstract][Full Text] [Related]
4. Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa.
Shiha G; Alswat K; Al Khatry M; Sharara AI; Örmeci N; Waked I; Benazzouz M; Al-Ali F; Hamed AE; Hamoudi W; Attia D; Derbala M; Sharaf-Eldin M; Al-Busafi SA; Zaky S; Bamakhrama K; Ibrahim N; Ajlouni Y; Sabbah M; Salama M; Anushiravani A; Afredj N; Barakat S; Hashim A; Fouad Y; Soliman R
Lancet Gastroenterol Hepatol; 2021 Jan; 6(1):57-64. PubMed ID: 33181119
[TBL] [Abstract][Full Text] [Related]
5. Present, Past,and Future of the Latin American Association for the Study of the Liver- Asociación Latinoamericana para el Estudio del Higado (ALEH).
Brahmand J; Contreras Peña FA
Ann Hepatol; 2018 Aug; 17(5):888-890. PubMed ID: 30145569
[TBL] [Abstract][Full Text] [Related]
6. Redefining fatty liver disease: an international patient perspective.
Shiha G; Korenjak M; Eskridge W; Casanovas T; Velez-Moller P; Högström S; Richardson B; Munoz C; Sigurðardóttir S; Coulibaly A; Milan M; Bautista F; Leung NWY; Mooney V; Obekpa S; Bech E; Polavarapu N; Hamed AE; Radiani T; Purwanto E; Bright B; Ali M; Dovia CK; McColaugh L; Koulla Y; Dufour JF; Soliman R; Eslam M
Lancet Gastroenterol Hepatol; 2021 Jan; 6(1):73-79. PubMed ID: 33031758
[TBL] [Abstract][Full Text] [Related]
7. Exploring the landscape of steatotic liver disease in the general US population.
Ciardullo S; Carbone M; Invernizzi P; Perseghin G
Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
[TBL] [Abstract][Full Text] [Related]
8. Editorial: The Metabolic (Dysfunction)-Associated Fatty Liver Disease (MAFLD) and Non-Alcoholic Fatty Liver Disease (NAFLD) Debate: Why the American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL) Consensus Process is Not Representative.
Fouad YM; Gomaa A; El Etreby RM; AbdAllah M; Attia D
Med Sci Monit; 2022 Aug; 28():e938066. PubMed ID: 35993179
[TBL] [Abstract][Full Text] [Related]
9. From NAFLD to MAFLD: Implications of a Premature Change in Terminology.
Younossi ZM; Rinella ME; Sanyal AJ; Harrison SA; Brunt EM; Goodman Z; Cohen DE; Loomba R
Hepatology; 2021 Mar; 73(3):1194-1198. PubMed ID: 32544255
[TBL] [Abstract][Full Text] [Related]
10. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.
Eslam M; Newsome PN; Sarin SK; Anstee QM; Targher G; Romero-Gomez M; Zelber-Sagi S; Wai-Sun Wong V; Dufour JF; Schattenberg JM; Kawaguchi T; Arrese M; Valenti L; Shiha G; Tiribelli C; Yki-Järvinen H; Fan JG; Grønbæk H; Yilmaz Y; Cortez-Pinto H; Oliveira CP; Bedossa P; Adams LA; Zheng MH; Fouad Y; Chan WK; Mendez-Sanchez N; Ahn SH; Castera L; Bugianesi E; Ratziu V; George J
J Hepatol; 2020 Jul; 73(1):202-209. PubMed ID: 32278004
[TBL] [Abstract][Full Text] [Related]
11. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement.
Eslam M; Alkhouri N; Vajro P; Baumann U; Weiss R; Socha P; Marcus C; Lee WS; Kelly D; Porta G; El-Guindi MA; Alisi A; Mann JP; Mouane N; Baur LA; Dhawan A; George J
Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):864-873. PubMed ID: 34364544
[TBL] [Abstract][Full Text] [Related]
12. Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease.
Chan WK; Tan SS; Chan SP; Lee YY; Tee HP; Mahadeva S; Goh KL; Ramli AS; Mustapha F; Kosai NR; Raja Ali RA
J Gastroenterol Hepatol; 2022 May; 37(5):795-811. PubMed ID: 35080048
[TBL] [Abstract][Full Text] [Related]
13. Editorial: The Metabolic (Dysfunction) Associated Fatty Liver Disease (MAFLD)-Non-Alcoholic Fatty Liver Disease (NAFLD) Debate: A Forced Consensus and The Risk of a World Divide.
Méndez-Sánchez N; Zheng MH; Kawaguchi T; Sarin SK
Med Sci Monit; 2022 Aug; 28():e938080. PubMed ID: 36017581
[TBL] [Abstract][Full Text] [Related]
14. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.
Eslam M; Sanyal AJ; George J;
Gastroenterology; 2020 May; 158(7):1999-2014.e1. PubMed ID: 32044314
[TBL] [Abstract][Full Text] [Related]
15. New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice.
Canivet CM; Boursier J; Loomba R
Semin Liver Dis; 2024 Feb; 44(1):35-42. PubMed ID: 38531378
[TBL] [Abstract][Full Text] [Related]
16. The NAFLD-MAFLD debate: Is there a Consensus-on-Consensus methodology?
Fouad Y; Dufour JF; Zheng MH; Bollipo S; Desalegn H; Grønbaek H; Gish RG
Liver Int; 2022 Apr; 42(4):742-748. PubMed ID: 35182007
[TBL] [Abstract][Full Text] [Related]
17. Reply to: correspondence regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement": Bringing evidence to the NAFLD-MAFLD debate.
Eslam M; George J
J Hepatol; 2020 Dec; 73(6):1575. PubMed ID: 32933781
[No Abstract] [Full Text] [Related]
18. Redefinition of fatty liver disease from NAFLD to MAFLD raised disease awareness: Mexican experience.
Méndez-Sánchez N; Díaz-Orozco L; Córdova-Gallardo J
J Hepatol; 2021 Jul; 75(1):221-222. PubMed ID: 33892008
[No Abstract] [Full Text] [Related]
19. Nonalcoholic Fatty Liver Disease in Latin America and Australia.
Castellanos-Fernandez MI; Pal SC; Arrese M; Arab JP; George J; Méndez-Sánchez N
Clin Liver Dis; 2023 May; 27(2):301-315. PubMed ID: 37024209
[TBL] [Abstract][Full Text] [Related]
20. Metabolic dysfunction-associated fatty liver disease: a year in review.
Alharthi J; Gastaldelli A; Cua IH; Ghazinian H; Eslam M
Curr Opin Gastroenterol; 2022 May; 38(3):251-260. PubMed ID: 35143431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
